Investor Meetings, New Clinical Data, Closing of Offering, and New Programs - Research Report on Teleflex, Orexigen, Sangamo,

Investor Meetings, New Clinical Data, Closing of Offering, and New Programs -
   Research Report on Teleflex, Orexigen, Sangamo, InterMune, and ImmunoGen

PR Newswire

NEW YORK, December 13, 2013

NEW YORK, December 13, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Teleflex
Incorporated (NYSE: TFX), Orexigen Therapeutics, Inc. (NASDAQ: OREX), Sangamo
Biosciences, Inc. (NASDAQ: SGMO), InterMune, Inc. (NASDAQ: ITMN), and
ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Teleflex Incorporated Research Report

On December 10, 2013, Teleflex Incorporated (Teleflex) announced the agenda
for its investor and analyst day meeting, to be held on December 17, 2013. The
Company informed that registration will open at 8:30 a.m. ET, along with
product displays. The Company noted that the meeting will include
presentations, from 9:00 a.m. ET to 12:00 p.m. ET, by Teleflex Chairman,
President and CEO Benson Smith and Executive Vice President and CFO Thomas
Powell, as well as presentations and Q&A with members of the senior management
team, and the Company will host a simultaneous webcast of these presentations.
The Full Research Report on Teleflex Incorporated - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/9c7d_TFX

Orexigen Therapeutics, Inc. Research Report

On December 6, 2013, Orexigen Therapeutics, Inc. (Orexigen) announced the
closing of its offering of $115 million aggregate principal amount of
convertible senior notes due 2020. The Company informed that the Notes bear
interest semi-annually at a rate of 2.75% per year, with maturity date of
December 1, 2020. Orexigen expects net proceeds from the offering of $110.5
million after deducting the initial purchasers' discounts and commissions and
the estimated offering expenses payable by it. The Company intends to use the
net proceeds for working capital and other general corporate purposes. The
Full Research Report on Orexigen Therapeutics, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/1b1a_OREX

Sangamo Biosciences, Inc. Research Report

On December 10, 2013, Sangamo Biosciences, Inc. (Sangamo) announced new
pre-clinical data that demonstrated therapeutic levels of gene modification in
non-human primates (NHPs) from its In Vivo Protein Replacement Platform. The
Company reported that data were presented at the 55^th Annual Meeting of the
American Society of Hematology. "These data provide proof of concept for this
broadly applicable genome editing strategy by demonstrating that our process
is scalable to large animals and by validating the use of the albumin safe
harbor as a site for expression of therapeutic proteins," said Philip Gregory,
D. Phil., Vice President of Research and Chief Scientific Officer at Sangamo.
"We have further optimized Sangamo's ZFN system and demonstrated that a single
systemic treatment enables stable liver-specific production of replacement
protein. Early data in primates suggest that we can achieve circulating levels
of protein above the threshold for therapeutic effect, which we believe are
sufficient for the correction of a range of monogenic diseases. Our data
demonstrate expression of replacement enzymes for multiple different proteins,
including those deficient in lysosomal storage disorders, which serves to
demonstrate the potential of this approach for a broad range of other
monogenic diseases." The Full Research Report on Sangamo Biosciences, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/52a6_SGMO

InterMune, Inc. Research Report

On December 10, 2013, InterMune, Inc. (InterMune) announced its support of the
Pulmonary Fibrosis Foundation to establish the Pulmonary Fibrosis Foundation
Care Center Network and Patient Registry. The Company reported that it expects
to launch the Care Center Network in 2014 with nine prestigious academic
medical centers implementing a care center model that combines high-quality
patient care with clinical research in order to collect essential information
from patients to build the Registry. "InterMune has spent more than a decade
committed to advancing the science of idiopathic pulmonary fibrosis (IPF) -
the most prevalent form of pulmonary fibrosis. As part of our ongoing
commitment, we are proud to support the Pulmonary Fibrosis Foundation to
establish its Care Center Network and Patient Registry. InterMune's vision is
to alter the course of IPF - a challenging and deadly disease - through the
development of new therapies that can provide hope to patients and their
families. We believe this work the Foundation is undertaking is a significant
step towards benefiting the IPF community," said Dan Welch, Chairman, CEO and
President of InterMune. The Full Research Report on InterMune, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/dd8c_ITMN

ImmunoGen, Inc. Research Report

On December 9, 2013, ImmunoGen, Inc. (ImmunoGen) announced clinical findings
with SAR3419 (coltuximab ravtansine) used in combination with Rituxan
(rituximab) to treat diffuse large B-cell lymphoma (DLBCL), which previously
had been treated with standard therapies. According to the Company, a total of
52 patients received SAR3419 and Rituxan in the trial, of which 45 were
evaluable for efficacy. Further, according to ImmunoGen, the data demonstrates
that the combination of SAR3419 and Rituxan was generally well tolerated, with
no patients discontinuing therapy due to treatment emergent adverse events
(TEAEs). The Full Research Report on ImmunoGen, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/11c8_IMGN

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)